CagriSema vs Lactoferricin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CagriSema
CagriSema is a fixed-ratio combination of cagrilintide (a long-acting amylin analog) and semaglutide, developed by Novo Nordisk. By combining two distinct appetite-regulating peptide hormones, CagriSema aims to achieve greater weight loss than semaglutide alone. Phase 3 data showed 22.7% body weight reduction, and an FDA response is expected in 2026.
Full details →Lactoferricin
Lactoferricin is an antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. It has potent antibacterial, antiviral, and antifungal properties.
Full details →Side-by-Side Comparison
| Aspect | CagriSema | Lactoferricin |
|---|---|---|
| Mechanism | CagriSema combines two complementary peptide mechanisms: (1) Semaglutide — GLP-1 receptor agonist providing glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and hypothalamic appetite suppression. (2) Cagrilintide — a long-acting analog of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. Amylin activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and hypothalamus, providing additional appetite suppression via a distinct neuronal pathway from GLP-1. The combination produces additive weight loss by engaging two independent satiety signaling systems. | Binds to and disrupts microbial membranes through electrostatic interactions. Also binds to lipopolysaccharide (LPS) to neutralize endotoxins and has immunomodulatory effects. |
| Typical Dosage | Phase 3 trial doses: cagrilintide 2.4 mg + semaglutide 2.4 mg weekly (fixed combination in a single injection). Dose escalation: start at cagrilintide 0.15 mg / semaglutide 0.25 mg weekly and escalate over 16 weeks to the maintenance dose. Administered as a single injection combining both peptides. | Research applications vary widely. Oral lactoferrin supplements (containing lactoferricin precursor) typically dosed at 100-400mg daily. |
| Administration | Single subcutaneous injection once weekly, combining both peptides. Pre-filled pen device. Not yet commercially available. FDA response expected 2026. | Available through lactoferrin supplementation orally. Purified lactoferricin primarily used in research settings. |
| Side Effects | Phase 3 data: nausea, vomiting, diarrhea, constipation (similar profile to semaglutide alone, but some reports suggest modestly higher GI rates). Decreased appetite. Injection site reactions. | Lactoferrin supplementation is generally well-tolerated. May cause GI upset in some individuals. Derived from milk so caution with dairy allergies. |
| Best For |
Key Differences
Unique to CagriSema:
Unique to Lactoferricin:
Detailed Analysis
Commonalities
CagriSema and Lactoferricin are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose CagriSema for Weight Loss, Diabetes Management. Choose Lactoferricin for Immune Support, Gut Health.
Ready to Learn More?
Looking for trusted sources?